🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to scientists.

A Global Challenge

Cases of gonorrhoea are increasing around the world, with estimates suggesting in excess of 82 million instances annually. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Health officials are increasingly worried about the increase in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in close succession. This treatment, which is employed against UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization GARDP partnered with the drug firm Innoviva to develop it.

“This milestone represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

According to data released by a major medical journal, the new drug eradicated more than 90% of cases of the STI. This establishes an comparable level with the existing first-line therapy, which involves two antibiotics. The study enrolled hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous regions with limited resources.

Medical professionals directly involved have voiced optimism. Having a easy-to-administer therapy of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to alleviate the strain of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.